AnneMarie Block, PhD, FACMG
AnneMarie Block, PhD, FACMG
Dr. AnneMarie W. Block joined the staff of Roswell Park Cancer Institute (RPCI) in 1985 as a Cancer Research Scientist and Clinical Cytogenetics Laboratory Supervisor. She was appointed Director, Clinical Cytogenetics Laboratory, Department of Pathology and Laboratory Medicine in 1988.
Dr. Block earned her doctoral degree in Physiology at UB in 1986. She is a Founding Fellow of the American College of Medical Genetics, a diplomate of the American Board of Medical Genetics (Clinical Cytogenetics, 1990), and has a New York State Certificate of Qualification as a Clinical Cytogenetics Laboratory Director.
Dr. Block is actively involved in graduate medical education and is the course coordinator for “Oncology for Scientists” (RPN 530-532) a year-long comprehensive survey course offered through the Roswell Park Graduate Division.
Dr. Block is a member of Cancer and Leukemia Group B, Children’s Oncology Group, American Society of Human Genetics, American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, American Association for the Advancement of Science, Association of Genetic Technologists, Association of Women in Science, American Association of University Women, Sigma Xi, American Society of Clinical Pathologists, American Association for Cancer Education, Inc., and the New York Academy of Sciences.
Dr. Block has authored or co-authored more than 150 journal publications, book chapters and abstracts. She is Assistant Editor for the journal Cancer Genetics and Cytogenetics.
Dr. Block’s research interests focus on chromosome abnormalities in B-cell lymphoproliferative disorders with an emphasis on tracking patient progress, survival, response to treatment and aid in therapeutic decision-making; mitogenic stimulation of human B cells; sister chromatid exchange analysis; chromosome aberration analysis; and fluorescence in situ hybridization (FISH) analysis of solid tumors and hematologic malignancies.
Sher T, Lee K, Block AW, Wood MT, Sood R, Bilgrami SA, Lawrence W, Miller A, Czuczman MS, Hernandez-Ilizaliturri F, Whitworth A, Lawrence D, Miller KC, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia and lymphoma 2010; 51(1):85-88
Morrison C, Nowak NJ, Block AW, McMeekin DS, Cohn D, Shepherd L, Liu S, Erwin DO, Kandel E, Dolce JM, Darcy KM, Miecznikowski J, Maxwell L. A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcome. Genes, chromosomes and cancer2010; 49(9):791-802
Wetzler M, Wang E, Thompson J, Baer M, Block AM, Sait S, Barcos M, Tighe S, Ford LA, Andrews C, Baumann H. Priming with arsenic trioxide improves the outcome of newly diagnosed acute myeloid leukemia patients < 60 years old treated with high-dose cytarabine and idarubicin. Haematologica 2010;95(Suppl. 2):Abstract #64
Derby L, Pendurti G, Deeb G, Sait S, Block A, Hernandez-Ilizaliturri FJ. Blastoid variant of mantle cell lymphoma (MCL) is associated with P53 abnormalities and have a shorter progression-free survival (PFS) and overall survival (OS) despite upfront chemo-immunotherapy followed by high dose chemotherapy and autologous stem cell support (HDC-ASCS). Blood 2010; 116(21):1773
Lee HJ, Trump D, Johnson CS, Wang ES, Thompson JE, Griffiths EA, Vigil CE, Barcos M, Block A, Sait S, Ford LA, Wilding G, Wei T, Muindi J, Wetzler M.Subnormal vitamin D levels are associated with adverse outcome in newly-diagnosed similarly-treated adult acute myeloid leukemia (AML) patients. Blood2010; 116(21):Abstract #1041
Block AW, Thompson JE, Wang ES, Starostik P, Deeb G, Sait SN, Ford L, Wilding GE, Groman AE, Wetzler M. The role of FLT3 in sole trisomy 8 acute myeloid leukemia. Journal of clinical oncology 2010; 28(15 Suppl.):6562
Harb AJ, Wang ES, Wallace PK, Barcos M, Block AW, Sait SNJ, Ford L, Wilding GE, Tan W, Wetzler M. Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models. Cancer 2009;115(11):2472-2481
Varadarajan R, Ford L, Sait SNJ, Block AW, Barcos M, Wallace PK, Ramnath N, Wang ES, Wetzler M. Metachronous and synchronous presentation of acute myeloid leukemia and lung cancer. Leukemia research 2009; 33(9):1208-1211
Noor SJ, Wang ES, Thompson JE, Block AW, Sait SN, Barcos M, Ford LA, Wilding GE, Tan W, Wetzler M. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases. Leukemia research2011; 35(5):608-613
Vigil C, Block AW, Wetzler M. The significance of quantifiable residual normal karyotype hematopoietic cells for toxicity and outcome. Leukemia and lymphoma 2011; 52(6):943
Arana-Yi C, Block AW, Sait SN, Ford LA, Barcos M, Baer MR. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine. Leukemia research 2008;32(7):1043-1048
Mrozek K, Holland KB, Sterling LJ, Edwards CG, Qumsiyeh MB, Block AW, Koduru PR, Heerema NA, Tantravahi R, Arthur DC, Watson MS, Pettenati MJ, Patil SR, Rao KW, Maharry K, Carroll AJ, Bloomfield CD. Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.International journal of oncology 2008; 33(2):239-244
Bartos JD, Stoler DL, Mittelman A, Petrelli NJ, Block A, Nowak NJ, Darbary H, Conroy JM, McQuaid DE, Gaile DP, Anderson GR. aCGH local copy number aberrations associated with overall copy number genomic instability in colorectal cancer: coordinate involvement of the regions including BCR and ABL. Mutation research. Fundamental and molecular mechanisms of mutagenesis 2007; 615(1-2):1-11
Abdelhalim A, Barcos M, Block AW, Sait SN, Starostik P, Wetzler M, Wang ES.Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. Leukemia and lymphoma 2007; 48(5):1053-1056
Battiwalla M, Sait S, Block AW, Kebbewar I, Ahluwalia MS, Timm EA, Wallace PK. Fluorescence activated cell sorting (FACs) followed by fluorescence in situ hybridization (FISH) to determine clonal origins of cells in Myelodysplastic syndrome (MDS) with paroxysmal nocturnal Hemoglobinuria (PNH). Blood2007; 110(11 Part 2):229B (Abstract #4623)
Noor S, Tan W, Wilding G, Ford LA, Barcos M, Sait SNJ, Block AW, Thompson JE, Wang ES, Wetzler M. Myeloid Blastic Transformation of Myeloproliferative Neoplasms - A Review of 113 Cases. Blood 2009; 114(22):1210
Varadarajan R, Licht A, Hyland AJ, Ford LA, Barcos M, Sait SNJ, Block AW, Baer MR, Thompson JE, Wang ES, Wetzler M. Smoking Adversely Affects Survival in Acute Myeloid Leukemia Patients. Blood 2009; 114(22):407
Lee HJ, Wright KM, Kandeel E, Tan W, Wilding GE, Ford LA, Sait SN, Block AMW, Barcos MP, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M. The role of minimal residual disease (MRD) by flow cytometry (FC) in predicting outcome in similarly treated acute lymphoblastic leukemia (ALL) patients : ASCO Meeting Abstracts Part 1.Journal of clinical oncology 2011; 29(15 Suppl.):6592
Wetzler M, Andrews C, Ford LA, Tighe S, Barcos M, Sait SN, Block AW, Nowak NJ, Baer MR, Wang ES, Baumann H. Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer 2011; 117(21):4861-4868
Lee HJ, Licht AS, Hyland AJ, Ford LA, Sait SN, Block AW, Barcos M, Baer MR, Wang ES, Wetzler M. Is obesity a prognostic factor for acute myeloid leukemia outcome?. Annals of hematology 2012; 91(3):359-365
Morzek K, Marcucci G, Maharry K, Nicolet D, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu YZ, Kohlschmidt J, Pettenati MJ, Koduru PRK, Heerema NA, Block AW, Patil SR, Baer MR, Kolitz JE, Moore JO, Carroll AJ, Larson RA, Bloomfield CD. Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts). Blood 2011; 118(21):190-191
Smonskey MT, Block AW, Deeb G, Chanan-Khan AA, Bernstein ZP, Miller KC, Wallace PK, Starostik P. Monoallelic and Biallelic Deletions of 13q14.3 in Chronic Lymphocytic Leukemia: FISH vs miRNA RT-qPCR Detection.American journal of clinical pathology 2012; 137(4):641-646
Varadarajan R, Licht AS, Hyland AJ, Ford LA, Sait SNJ, Block AW, Barcos M, Baer MR, Wang ES, Wetzler M. Smoking adversely affects survival in acute myeloid leukemia patients. International journal of cancer 2012; 130(6):1451-1458
Minderman H, Arcadi JC, Wierzbicki A, Wang ES, Sait SNJ, Block AW, Liang L, George T, Wallace PK. Detection of Numerical Chromosome Aberrations in Rare Acute Myeloid Leukemia (AML) Cells. Haematologica 2009; 94(Suppl. 2):0037
Padmanabhan S, Block AW, Wallace P, Tan W, Nowak N, Varadarajan P, Barcos M, Hernandez F, Ketepalli S, Wilding G, Czuczman M, Chanan-Khan A.Concomitant z score and ZAP 70 along with ATM deletion identifies patients with poor survival from the RPCI Chronic Lymphocytic Leukemia Series: A correlation of treatment and survival of B-CLL patients with prognostic variables such as fish, ZAP70 expression, CGH. Haematologica 2008;93(Suppl. 1):416 (Abstract #1053)
Sardesai SD, Tan W, Ford LA, Deeb G, Block AMW, Sait SNJ, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M.Predicting outcome based on minimal residual disease (MRD) using multiparameter flow cytometry (FC) in acute myeloid leukemia (AML) patients (Pts) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6565
Minderman H, Humphrey K, Arcadi JK, Wierzbicki A, Maguire O, Wang ES,Block AW, Sait SN, George TC, Wallace PK. Image cytometry-based detection of aneuploidy by fluorescence in situ hybridization in suspension. Cytometry. Part A 2012; 81A(9):776-784